GlassScriptPhysician profile
Benjamin John Dorfman
NPI 1043697709
$3,665.12
in general payments reported to CMS, 2019-2025
26 companies · $871 in 2025
The $871 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $75.93 · 2021: $310 · 2022: $650 · 2023: $254 · 2024: $795 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.28 |
| Education | $263.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $567.76 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Merz Pharmaceuticals, LLC | $341.70 | 2021-2025 | Xeomin, Inbrija |
| Mdd US Operations, LLC | $292.38 | 2024-2025 | Gocovri |
| Abbvie INC. | $286.44 | 2022-2025 | Duopa |
| Allergan, INC. | $264.55 | 2019-2021 | |
| Medtronic USA, INC. | $259.32 | 2019 | |
| Abbott Laboratories | $217.40 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $214.18 | 2022-2023 | Rytary |
| Neurocrine Biosciences, INC. | $163.60 | 2021-2023 | Ongentys, Ingrezza |
| Acadia Pharmaceuticals INC | $162.25 | 2022-2024 | |
| Merz North America, INC. | $125.00 | 2019 | |
| Lundbeck LLC | $120.86 | 2019-2025 | Rexulti, Vyepti |
| Biogen, INC. | $115.32 | 2024 | Skyclarys |
| Boston Scientific Corporation | $110.90 | 2022 | |
| Supernus Pharmaceuticals, INC. | $83.26 | 2025 | Qelbree |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $53.01 | 2024-2025 | Nourianz |
| Eisai INC. | $46.45 | 2024-2025 | |
| Ge Healthcare | $38.29 | 2025 | |
| Cala Health, INC. | $38.00 | 2022 | |
| Acorda Therapeutics, INC | $36.77 | 2022-2023 | Inbrija |
| Averitas Pharma INC. | $31.58 | 2024 | Qutenza |
| Lilly USA, LLC | $21.46 | 2024 | Amyvid |
| Azurity Pharmaceuticals, INC. | $20.72 | 2024 | Horizant |
| Avion Pharmaceuticals | $20.01 | 2023 | Dhivy |
| Tanabe Pharma America, INC. | $18.28 | 2025 | Radicava |
| Sunovion Pharmaceuticals INC. | $15.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Dorfman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.